2010

January 8

Svelte Medical Systems, Inc. Announces the Initiation of its European Clinical Trial and the expansion of its Executive Management Team

2009

December 7	Svelte Medical Systems, Inc. Successfully Raises $6M in Private Funding
December 4	Svelte Medical Systems Named a Top Innovator Winner
November 18	Asterand Issues Interim Management Statement and Announces Agreement to Acquire BioSeek
November 9	Ikano Therapeutics Receives Orphan Drug Designation for Epilepsy Drug
October 14	ZyStor Cleared to Begin Clinical Trial
August 11	Kereos Article, Bee Venom Destroys Cancer Cells in Tests on Mice
June 30	Asterand plc Interim Results for the Period Ended 30 June 2009
May 11	Nephrion, Inc. Announces R. James Danehy as President and Chief Executive Officer
May 7	Triathlon Medical Hires Sooch, Eyes $150M Second Fund
May 5	Svelte Medical Systems, Inc. Licenses Stent Design and Delivery System Technology from Cordis Corporation
March 30	Asterand plc Preliminary Results Statement for the year ended 31 December 2008
March 13	Wide-ranging restructuring bears fruit for Asterand
March 3	Intranasal Becomes Ikano, Nabs $18M Series B
February 9	Asterand sees first yearly profit, wants acquisitions, partnership
January	Asterand 2008 Share Performance

2008

November 11	Asterand Plc Interim Management Statement
August 27	Asterand to Enter Into Exclusive License Agreement with Allergan for Pre-Clinical Compounds Focused on Diseases of the Eye
July 8	Intranasal Therapeutics Names Jeffrey Edelson, MD, Executive Vice President, R&D and Chief Medical Officer
June 17	Asterand plc Board Appointments
May 19	Asterand plc Interim Management Statement
April 4	Asterand plc Announces Preliminary Results for 2007
April 2	Kereos Article, Nano-sized technology has super-sized effect on tumors
April	The Fischell Family's Secret of Success
March 19	ProNAi Cleared to Begin Phase I Clinical Trials

2007

December 24	ProNAi: The Other Interference
October 18	Business Weekly-10 Questions to Asterand CEO Martyn Coombs
October 3	Asterand Awarded US Government Contract to Evaluate World’s Largest Tissue Repository
June 6	Asterand plc - Strategy Announcement
May 9	Asterand plc Annual General Meeting Statement 9 May, 2007
April 17	ProNAi Announces Preclinical Success For PNT2258 Therapeutic - Curative Events in Xenograft Mice For Difficult-To-Treat Non-Hodgkin's Lymphoma
April 4	ITI Appoints Pharmaceutical Industry Veteran, Peter F. Young, as President and CEO
March 27	Martyn Coombs Appointed As a Director and CEO of Asterand plc
March 6	ProNAi and Novosom AG Announce Collaboration to Enable Delivery of DNAi®-based Cancer Therapeutics
January 8	ProNAi Announces DNA Interference (DNAi®) Drug Development Strategy for 2007

2006

December 6	Intranasal Therapeutics, Inc. Adds Key Executives to Management Team
September 29	Published Data Shows Kereos Technology Specifically Targets Arterial Plaque
September 26	ProNAi Announces Executive Team Buildup and new CEO Richard Gill
September 25	Asterand Annouces 2006 Interim Trading Results
September 7	Renamed Biologics Secures $40M in Private Equity Financing
August 15	ITI Closes $39M Series A Venture Financing
July 31	Asterand Plc Annual Shareholders Meeting Statement and CEO Succession Plans
July 25	ITI Study shows Potential of IntraNasal Midazolam as Effective Sedative
May 11	Asterand offers new cell line to speed cancer research
April 17	Asterand Announces New Test to Reduce Risks in Human Drug Trials
March 28	RenaMed Biologics to Expand Operations to Westborough, MA
March 23	Gary Stroy Takes Helm At Neuralieve after Afmedica
March 20	Asterand PLC Announces Preliminary Results for 2005
March	Positive Partnering - Apjohn Group Article at University of Minnesota
February 23	Asterand, Backed By State and WSU, Building World Bank For Human Tissue Samples
January 27	BTG Licenses Analgesic Compounds from Asterand

2005

December 13	Kereos Appoints Pfizer Veteran to Lead Pharmacology, also Announces New Directors
November 15	Kereos' Collaborators Present On Targeted Therapies For Cardiovascular Disease
November 12	RenaMed Biologics Reports Positive Phase II Data With Renal Bio-Replacement Therapy
October 19	ProNAi Raises $4.25M to Develop a New Class of Therapies That Target DNA
October 7	Angiotech Completes Acquisition of Afmedica
September 28	RenaMed Biologics and Genzyme Announce Worldwide Collaboration to Advance Treatment for Acute Renal Failure
September 20	Kereos Secures $19.5 Million in Series B Financing
September 19	Merger of Pharmagene and Asterand to Form Leading Company in Human Tissue Supply and Research Services
July 11	Michigan Drives For Biotech Industry, But The Road Can Be Bumpy
June 9	Human Tissue Co. Asterand Closes On $3.5M Series D
June 9	Detroit's Asterand Voted Best Place To Work For Scientists
April 18	Venture Michigan Fund Announces Fund Man as Credit Suisse First Boston
March 8	Grand Angels Go Biopharm, Local Group Invests In ProNAi Therapeutics, Inc.
March 7	Afmedica Press Release Announcing New CEO Gary Stroy
March 1	Asterand Becoming World Class Life Sciences Asset For Michigan
February 6	Impact Of Pfizer Acquisition Of Esperion Ripples Through Michigan Life Sciences Industry A Year Later

2004

December 15	Zystor Therapeutics Completes First Financing
June 21	Scientists Vote Detroit's Asterand "Best Place To Work."
April	Michigan Business Report, Apjohn Creating Life Sciences Opportunities

2003

November 21

Asterand Raises Series "C" Financing